Objectives: Chemoresistance development represents a major obstacle to the successful treatment of colorectal cancer (CRC). The aim of this study was to elucidate the mechanism by which miR-506 reverses oxaliplatin chemoresistance in CRC. 
The poor patient prognoses associated with CRC are partially due to resistance to existing therapies; however, our understanding of the mechanisms underlying therapy resistance, as well as the number of available therapeutic options, remains limited. This study found that chemotherapy effectiveness is often limited by abnormal drug resistance-related protein expression. Common drug resistance proteins include glutathione-s-transferase (GST), lung resistance-related protein (LRP), multi-drug resistance-associated protein 1 (MRP1) and permeability-glycoprotein (P-gp). 2 Overexpression of these proteins results in acquired and/or intrinsic drug resistance in many tumours.
However, thus far, the complex mechanisms underlying the effects exerted by these proteins have not been fully elucidated. MicroRNAs (miRNAs) are a class of small, single-stranded, non-coding RNA molecules of 19-24 nucleotides in length 3, 4 and have been reported to play an important role in drug resistance in both haematopoietic and solid tumours, [5] [6] [7] including CRC. [8] [9] [10] [11] [12] Zhou 13 reported that miR-203 induces oxaliplatin resistance in CRC cells by negatively regulating ATM kinase. chromosome-linked miRNA cluster that has been reported to function both as an oncogene and as a suppressor of tumour progression. 15 In our previous study, we confirmed that the miR-506-EZH2 axis modulates CRC invasion and metastasis by inhibiting the Wnt/β-catenin signalling pathway. 16 However, little work has been performed regarding the relationship between miR-506 and oxaliplatin resistance in chemoresistant CRC cells.
miR-506 has been identified as a tumour suppressor in CRC; however, the role of miR-506 in CRC chemoresistance has not been fully studied. In this study, we confirmed that miR-506 is down-regulated in chemoresistant CRC cancer tissues, which is associated with a poor prognosis. We also found that miR-506 inhibited MDR1/P-gp expression via down-regulation of the Wnt/β-catenin pathway to reverse oxaliplatin resistance in HCT116-OxR cells. These results enhanced our understanding of the molecular mechanisms underlying CRC drug resistance and indicated that miR-506 may be a therapeutic target in chemoresistant CRC.
| MATERIALS AND METHODS

| Ethics statement
All patients agreed to participate in the study and provided written informed consent. This study was approved by the ethics board of the Third XiangYa Hospital of Central South University and complied with the Declaration of Helsinki.
| Patient samples
The study enrolled 74 patients with confirmed advanced CRC, including patients diagnosed with stage IV CRC through colonoscopy and magnetic resonance or computed tomography (CT) scan before chem- 
| Cell culture
The human CRC HCT-116 cells used in this study were purchased from American Type Culture Collection. HCT-116 cells and HCT116-OxR cells were cultured in RPMI 1640 medium (Gibco Industries,
Inc. Carlsbad, CA, USA), and the medium was supplemented with 10% foetal bovine serum, 100 U/mL penicillin G and 100 μg/mL streptomycin. Oxaliplatin-resistant HCT-116 cell (HCT116-OxR) was established by our laboratory. Briefly, 20 ng/mL of oxaliplatin was used in the beginning to induce drug resistance of HCT-116 cell line, and thereafter, the concentration of oxaliplatin was increased in gradient. About 7 months later, the cells could stably grow in 20 μg/mL of oxaliplatin, which was named HCT116-OxR cell line.
The HCT116-OxR cells were seeded in the medium additionally contained 5 μg/mL oxaliplatin, so as to maintain the drug-resistant phenotype. Both cell lines were incubated in 5% CO 2 at 37°C in 100% humidity.
| In situ hybridization analysis
In situ hybridization (ISH) analysis was performed according to a previously described method. 18 Antisense oligonucleotide probes for miR-506 (Exiqon Inc., Woburn, MA, USA) were used for ISH. for 1 hour at room temperature, followed by incubation with secondary antibody conjugated with FITC. DAPI (0.1 μg/mL) was added to the secondary antibody mixture to visualize nuclei. Fluorescence images were collected and analysed using an inverted fluorescence microscope. 
| Immunofluorescence staining
| Cell cycle analysis
| Apoptosis analysis
Cell apoptosis analysis was performed using a Phycoerythrin (PE)- Cell viability was measured via MTT assay.
| MTT assay and drug sensitivity assay
| Western blot
Total proteins were harvested from cultured cells or fresh frozen tissues and lysed by ice-cold lysis buffer. Proteins were separated via 6% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5%
non-fat milk in PBS for 1 hour at room temperature and then immunoblotted with the following primary antibodies: rabbit-anti-human P-gp, MRP1, LRP, GST (1:1000; Affinity biosciences Inc, OH, USA) and β-actin (1:800; Affinity biosciences Inc, OH, USA), followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:5000;
Bioworld Technology, Inc, NanJing, China) for 1.5 hours at room temperature. Reactive bands were visualized using an enhanced chemiluminescence system. Band intensity was quantified using an image analysis system (Quantity One v4.62, Bio-Rad Laboratories Co., Ltd.
Hercules, CA, United States). The experiment was repeated three times.
| Quantitative RT-PCR
Total RNA was extracted from cells or tissues using TRIzol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. For mature miR-506 detection, total RNA was polyadenylated using poly(A) polymerase (Ambion, Austin, TX, USA), as described previously.
Reverse transcription was performed using poly(A)-tailed total RNA, a reverse transcription primer and ImPro-II Reverse Transcriptase Germany). U6 was used as an internal control; other specific primers were purchased from Invitrogen.
| miRNA transfection
The miRNA-506 mimic and negative control were obtained from 
| Statistical analysis
All values are expressed as the mean ± standard deviation (SD). The significance of the differences was determined via one-way ANOVA or Student's t-test. An χ 2 test was used to evaluate the relationship between expression and patient clinicopathological characteristics.
The Kaplan-Meier method was employed for survival analysis, and the differences in survival probability were estimated using the log-rank test by Prism software (GraphPad Software 6). P<.05 was considered statistically significant. Statistical analysis was performed using spss version 20.0 (SPSS, Inc., Chicago, IL, USA).
| RESULTS
| miR-506 expression was down-regulated in chemoresistant CRC cancer tissues and was correlated with survival
To study the expression levels of miR-506 in chemotherapy-treated CRC tissues, mature miR-506 was analysed in 31 NR CRC tissue samples and 43 R CRC tissue samples via qRT-PCR. The expression of miR-506 is no difference between the pre-chemotherapy and after chemotherapy in the NR CRC tissue samples ( Figure 1A ). In the R CRC tissue samples, the expression of miR-506 is higher in the prechemotherapy than after chemotherapy ( Figure 1B ). ISH analysis showed that miR-506 expression was significantly down-regulated in NR CRC tissue samples compared to R CRC tissue samples (P<.05, Figure 1D ), and the qRT-PCR results indicated that miR-506 is downregulated in chemoresistant CRC (P<.05, Figure 1C ). We further F I G U R E 1 miR-506 expression was down-regulated in chemoresistant colorectal cancer (CRC) tissues and correlated with survival. A, The relative expression levels of miR-506 were assessed via qRT-PCR between pre-chemotherapy (pNR CRC) and after chemotherapy in 31 non-responder colorectal cancer (NR CRC) tissues. B, The relative expression levels of miR-506 were assessed via qRT-PCR between prechemotherapy (pR CRC) and after chemotherapy in 43 responder colorectal cancer (R CRC) tissues. C, The relative expression levels of miR-506 were assessed via qRT-PCR in 43 R CRC tissues and 31 NR CRC tissues. D, Analysis of miR-506 expression in chemoresistant CRC cancer tissues and non-chemoresistant CRC cancer tissues by in situ hybridization (ISH) (×400). E, Kaplan-Meier analysis revealed that the OS and RFS rates of the high miR-506 expression group was higher than those of the low miR-506 expression group (*P<.05)
analysed the relationship between the miR-506 expression levels and the clinicopathological characteristics of CRC patients ( 
| Correlation between resistance-related gene expression and protein and miR-506 levels in HCT116-OxR cells
To elucidate the mechanism underlying the miR-506-mediated reversal of oxaliplatin resistance in CRC, the gene and relative protein expression levels of MDR1, LRP, GST and MRP1 in miR-506-transfected
HCT116-OxR cells were evaluated via qRT-PCR and Western blotting
(WB) ( Figure 3A ,B). MDR1/P-gp expression was lower in HCT116-
OxR-miR-506 cells than in HCT116-OxR and HCT116-OxR-Ctrl cells (P<.05).
A similar result was observed via IF staining ( Figure 3C ). These findings indicate that miR-506 strengthens the sensitivity of HCT116-OxR cells to oxaliplatin by inhibiting P-gp expression. 
| miR-506 up-regulation in HCT116-OxR cells inhibited MDR1/P-gp expression via the Wnt/β-catenin pathway
Studies have revealed that the Wnt/β-catenin signalling pathway plays an important role in cell proliferation, differentiation, invasion, migration and chemoresistance in many types of cancers. Our previous study showed that miR-506 acts as a negative regulator of β-catenin to inhibit the Wnt/β-catenin pathway. Shen 20 and Zhang 21 showed that inhibition of Wnt/β-catenin signalling down-regulates P-gp and reverses multi-drug resistance in cholangiocarcinoma and ovarian cancer. Therefore, we speculated that miR-506 may play an important role in the inhibition of MDR1/P-gp expression by down-regulating Wnt/β-catenin signalling pathway activity. To validate this infer- Many agents that modulate the function of P-gp have been identified, including calcium channel blockers, calmodulin antagonists, steroidal agents, protein kinase C inhibitors, immunosuppressive drugs, antibiotics and surfactants. 22 Improving chemosensitivity by targeting P-gp has been extensively used as a strategy for cancer therapy.
A few studies have used oxaliplatin-resistant CRC cells as a model. 
Axin2 (AXIN2) and matrix metalloproteinases. It was reported that
Wnt/β-catenin signalling plays an important role in the induction of MDR1/P-gp expression. 21 Shen 20 revealed that inhibition of Wnt/ β-catenin signalling down-regulates MDR1/P-gp expression and reverses multi-drug resistance in cholangiocarcinoma. Yamada 28 suggested that MDR1 is a target gene of the TCF4/β-catenin complex.
Down-regulation of Wnt/β-catenin signalling repressed MDR1/P-gp expression, inducing apoptosis in multifarious human cancer cells and validating the function of the Wnt/β-catenin signalling pathway in CRC. 28, 29 The Wnt/β-catenin signalling pathway is altered in more than 90% of patients with CRC 30 which makes it a particularly attractive therapeutic target. Hence, disruption of the Wnt/β-catenin signalling pathway may represent an opportunity for improved CRC chemoprevention and therapy. Several miRNAs are regarded as regulators and regulate Wnt/β-catenin signalling pathway activity. [31] [32] [33] [34] However, the mechanism by which miR-506 reverses oxaliplatin che- In summary, we have demonstrated a novel miRNA-mediated regulatory mechanism by which miR-506 reverses MDR1/P-gp-mediated chemoresistance by repressing the Wnt/β-catenin signalling pathway through β-catenin down-regulation. Our present study has provided strong evidence that miR-506 up-regulation may represent a promising chemosensitization strategy for the treatment of CRC.
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